---
title: "Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278199180.md"
description: "Novo Nordisk and Hims & Hers Health have reportedly resolved their legal dispute and are set to announce a partnership for selling Novo's weight-loss drugs on Hims' telehealth platform. This news has led to a significant increase in Hims' stock price, which surged nearly 40% in after-hours trading. The partnership comes after a previous lawsuit from Novo Nordisk over patent violations related to a compounded version of its weight-loss drug. The market for obesity drugs is becoming increasingly competitive, with scrutiny on copycat products from the FDA."
datetime: "2026-03-07T02:52:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278199180.md)
  - [en](https://longbridge.com/en/news/278199180.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278199180.md)
---

# Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report

**Novo Nordisk AS** (NYSE:NVO) and **Hims & Hers Health Inc.** (NYSE:HIMS) have reportedly ended their public feud, with the drugmaker deciding to sell its weight-loss drug on the telehealth platform.

The announcement regarding the new partnership is expected as soon as Monday, Bloomberg reported on Friday, citing a person familiar with the matter.

Last month, Novo Nordisk sued Hims & Hers after the latter began marketing a compounded version of its new weight-loss pill. The company alleged patent violations, citing the ingredient used in Wegovy.

In 2025, Novo Nordisk and Hims & Hers also announced a partnership, but the drugmaker ended the agreement abruptly after the platform declined to stop promoting the compounded versions of the drugs.

“We are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases. These talks happen on an ongoing basis, and we will discuss if/when we have final details to share,” a Novo Nordisk spokesperson told Benzinga in an emailed statement.

Hims & Hers did not immediately respond to Benzinga's request for comment.

## **Weight-Loss Drug Market Pressure Builds**

Novo Nordisk has been facing tough competition in the obesity drugs market. The company's biggest rival is **Eli Lilly and Company** (NYSE:LLY) and telehealth platforms that offer compounded versions of GLP-1 drugs.

The competition has grown due to the recent supply shortages. However, the U.S. Food and Drug Administration has indicated plans to increase scrutiny of copycat weight-loss drugs.

**Price Action:** After-hours trading saw shares of Hims & Hers Health surge 39.77% to $22, after closing Friday down 0.88% at $15.74. Shares of Novo Nordisk closed at $38.58 on Friday, down 1.25%, but rose 2.12% to $39.40 in after-hours trading, according to Benzinga Pro.

**Benzinga's Edge Stock Rankings** show that Novo Nordisk is exhibiting weakness across the short, medium, and long-term, although its Quality score ranks in the 76th percentile.

_Image via Shutterstock_

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Hims & Hers' Shift to Branded Obesity Drugs Pressures Stock — Will the Bet Pay Off?](https://longbridge.com/en/news/282190695.md)
- [RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?](https://longbridge.com/en/news/283044988.md)
- [How RFK Jr. sent Hims & Hers stock higher](https://longbridge.com/en/news/283031976.md)
- [Hims & Hers (HIMS) Shifts Beyond GLP-1 Controversy to Long-Term Health Platform](https://longbridge.com/en/news/282500365.md)
- [The definitive infrastructure for modern drug development](https://longbridge.com/en/news/283027097.md)